MAO/DETECTION OF ANTIBODIES & PROTEINS--ISOLATION OF VIR

MAO/抗体检测

• 批准号: 2296474
• 负责人: RANAJIT PAL
• 金额: $ 13.92万
• 依托单位: ADVANCED BIOSCIENCE LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-09-30 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2296474
• 关键词: MAO; DETECTION; ANTIBODIES; PROTEINS; ISOLATION

The HIV Preclinical Vaccine Development Master Agreement Program was initiated to enable the NIAID to provide resources to accelerate the development of promising vaccine approaches. Under this program, a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates. These studies are designed to obtain more information about the efficacy and optimum presentation of candidate HIV vaccines that are in human Phase I clinical trials or proposed for such trials as well as prototype SIV vaccines of the same type as these HIV vaccines Other vaccine studies will evaluate prototype HIV or SIV vaccines that offer novel presentation systems, may be capable of eliciting broadly cross-reactive immune responses, or have shown promising preliminary results. NIAID has initiated collaborative arrangements with researchers who have agreed to provide HIV and SIV vaccines for immunization of nonhuman primates. In all of the vaccine studies, the nonhuman primates will be challenged after immunization to determine if protection from infection or from disease can be obtained. The contractors in Category E of the Master Agreement Program, including the contractor listed above, will provide the laboratory support for these various vaccine studies. The laboratory support work is divided into two parts. Part A pertains to animals immunized with HIV vaccines and challenged with SHIV, and Part B assays pertain to animals immunized with SIV vaccines and challenged with SIV. In all cases assays will be performed such as ELISA and Western Blots to assess the humoral immune responses of immunized macaques. Virus isolations such as co-culture and limiting dilution will be performed to determine if virus infection has occurred after virus challenge. The Category E contractors will maintain a test results database for each study, and will transfer data electronically to the AIDS Vaccine Evaluation Group Statistical and Coordinating Center. In addition, the Category E contractors will provide facilities and equipment to conduct biosafety level 2 or 3 laboratory work.

HIV临床前疫苗开发主协议计划 启动以使NIAID能够提供资源，以加速 开发有前景的疫苗方法。在这个项目下，一系列 已经启动了疫苗研究，以评估候选疫苗， 在非人类灵长类动物中的原型艾滋病疫苗。这些研究旨在 以获得更多关于功效和最佳呈现的信息， 在人体I期临床试验中的候选HIV疫苗，或 以及相同的原型SIV疫苗 其他疫苗研究将评估原型 提供新的呈递系统的HIV或SIV疫苗可能能够 引发广泛的交叉反应性免疫反应，或者已经显示 有希望的初步结果。NIAID已启动合作 与同意提供艾滋病毒和SIV的研究人员达成协议， 用于非人灵长类动物免疫的疫苗。在所有的疫苗中 研究中，非人灵长类动物将在免疫后受到挑战， 确定是否可以获得免受感染或疾病的保护。 主协议计划E类承包商，包括 上述承包商将提供实验室支持， 这些疫苗研究。实验室支持工作分为 分成两部分。A部分涉及用HIV疫苗免疫的动物 并用SHIV攻毒，B部分试验适用于免疫动物 用SIV疫苗进行攻击。在所有情况下， 进行如ELISA和Western印迹，以评估体液免疫 免疫猕猴的反应。病毒分离，如共培养和 将进行有限稀释，以确定病毒感染是否 病毒攻击后发生。E级承建商须 每个研究的测试结果数据库，并将传输数据 艾滋病疫苗评价小组统计和 协调中心。此外，E级承建商亦会提供 进行生物安全2级或3级实验室的设施和设备 工作